IP Library › Granted Patent US 12,706,179
Granted Patent B2
US 12,706,179 · App. 18/358,388 · Granted Aug 11, 2026

Population based treatment recommender using cell free DNA

Inventors: Helmy Eltoukhy (Atherton, CA); AmirAli Talasaz (Atherton, CA)
Assignee: GUARDANT HEALTH, INC.
G16B50/20C12Q1/6883G16B40/00G16B40/20G16B40/30G16B50/00G16H20/00G16H50/30C12Q1/6886
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,706,179
App. No.
18/358,388
Filed
Jul 25, 2023
Granted
Aug 11, 2026
Kind
B2
Art Unit
1685
USPC
706/12
Abstract

Systems and methods are disclosed for generating a therapeutic response predict or detecting a disease, by: using a genetic analyzer to generate genetic information; receiving into computer memory a training dataset comprising, for each of a plurality of individuals having a disease, (1) genetic information from the individual generated at first time point and (2) treatment response of the individual to one or more therapeutic interventions determined at a second, later, time point; and implementing a machine learning algorithm using the dataset to generate at least one computer implemented classification algorithm, wherein the classification algorithm, based on genetic information from a subject, predicts therapeutic response of the subject to a therapeutic intervention.

Claims (37)

1 . A method, comprising:

obtaining or having obtained a cell-free biological sample comprising cell-free DNA (cfDNA) molecules from a subject from at least two different time points;

generating a plurality of sequencing reads from the cfDNA molecules;

identifying, in the plurality of sequencing reads, genetic variants comprising sequence variants and copy number variants;

quantifying the frequency of genetic variants;

generating an initial diagnostic confidence indication based on the genetic variants and frequencies of the genetic variants from the first of the at least two different time points;

generating an adjusted diagnostic confidence indication based on conflict or corroboration of the genetic variants and frequencies of the genetic variants from the second of the at least two different time points;

storing genetic information comprising the genetic variants and frequencies of the genetic variants and clinical information comprising initial and adjusted diagnostic confidence indications of the subject in at least one database;

obtaining genetic information from each of a plurality of subjects in the at least one database;

operably connecting at least one extractor to the at least one database, wherein the extractor is configured to extract one or more features from the genetic and clinical information stored in the at least one database; and,

operably connecting at least one treatment efficacy monitor to the at least one extractor, operably connecting at least one classifier to the extractor and to the recommender, wherein the classifier is configured to classify the one or more features extracted from the genetic and clinical information, and wherein classifier training comprises:

(a) providing a plurality of different classes, wherein each class represents a set of subjects with a shared characteristic;

(b) providing a multi-parametric model representative of the cfNAs from each of a plurality of samples belonging to each of the classes, thereby providing a training data set; and

(c) training a learning algorithm on the training data set to create one or more trained classifiers, wherein each trained classifier comprises one or more random forests, linear classifiers, support vector machines, and/or Hidden Markov models (HMMs), and classifies a test sample into one or more of the plurality of classes, thereby generating the system;

wherein the at least one treatment efficacy monitor is configured to:

implement the one or more trained classifiers to determine treatment efficacy for at least one treatment from among a plurality of treatment options for a cancer of at least one test subject of the plurality of subjects, based at least in part on an analysis of the one or more features at a first time point of the two or more time points; and

implement the one or more trained classifiers to determine an effective treatment from among a plurality of treatment options for a cancer of at least one test subject of the plurality of subjects, wherein selection of the treatment, based on at least an analysis of the:

one or more features comprising genetic information for the given subject from a second time point of the two or more time points; and

amount of time between at least two or more time points.

2 . The method of claim 1 , wherein the plurality of subjects comprises subjects having cancer.

3 . The method of claim 1 , wherein the plurality of subjects comprises cancer-free subjects.

4 . The method of claim 1 , further comprising operably connecting at least one genetic analyzer to the system, wherein the genetic analyzer is configured to the genetic information.

5 . The method of claim 1 , further comprising operably connecting at least one report generator to the recommender.

6 . The method of claim 1 , wherein the genetic information comprises unstructured text data.

7 . The method of claim 1 , comprising storing the clinical information in at least one database array.

8 . The method of claim 1 , wherein the clinical information comprises patient information from physicians and test labs.

9 . The method of claim 1 , wherein the clinical information comprises CT scans, MRI scans, ultrasound scans, bone scans, PET scans, bone marrow tests, X-rays, endoscopies, lymphangiograms, intravenous urograms (IVU), IV pyelograms (IVP), lumbar punctures, cystoscopies, immunological tests, histology reports, and/or cancer marker tests.

10 . The method of claim 1 , further comprising using the system to predict a course of treatment for at least one test subject having cancer.

11 . The system generated by the method of claim 1 .

12 . The method of claim 1 , wherein the plurality of different classes is selected from the group consisting of: cancer-free, breast cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, melanoma, and liver cancer.

13 . The method of claim 1 , wherein the one or more features comprise treatment responses to therapeutic interventions to generate one or more treatment classifications.

14 . The method of claim 13 , wherein the one or more treatment classifications comprise responsive to treatment, nonresponsive to treatment, or a level of responsiveness to treatment.

15 . The method of claim 1 , further comprising operably connecting at least one inference unit to the classifier and to the recommender.

16 . The method of claim 15 , wherein output of the classifier is provided to the inference unit.

17 . The method of claim 1 , wherein a diagnostic confidence indication can be increased in the subsequent characterization if the information from a first time point corroborates information from the second time point.

18 . The method of claim 1 , wherein diagnostic confidence indication can be decreased in the subsequent characterization if the information from a first time point conflicts with information from the second time point.

19 . The method of claim 1 , comprising detecting genetic variants in the noise range of a machine configured to generate the plurality of sequencing reads.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2023
From: ELTOUKHY, HELMY; TALASAZ, AMIRALI
To: GUARDANT HEALTH, INC.
Reel/Frame 064485/0321 →
Continuity (4)
Continuation 17003631 · Aug 26, 2020
Continuation 15766765 · Oct 7, 2016
Provisional Application 62239390 · Oct 9, 2015
Related Publication 20240153593A1 · May 9, 2024
References Cited (33)
US 9109256B2 · Shuber · 2015 [cited by applicant]
US 11756655B2 · Eltoukhy · 2023 [cited by examiner]
US 20020029113A1 · Wang et al. · 2002 [cited by applicant]
US 20020077756A1 · Arouh et al. · 2002 [cited by applicant]
US 20040111169A1 · Hong et al. · 2004 [cited by applicant]
US 20050234570A1 · Horsch et al. · 2005 [cited by applicant]
US 20080161420A1 · Shuber · 2008 [cited by applicant]
US 20090233279A1 · Glinskii · 2009 [cited by applicant]
US 20100041048A1 · Diehl et al. · 2010 [cited by applicant]
US 20100063948A1 · Virkar et al. · 2010 [cited by applicant]
US 20100221754A1 · Ford et al. · 2010 [cited by applicant]
US 20110166030A1 · Wang et al. · 2011 [cited by applicant]
US 20140031260A1 · O'Donnell · 2014 [cited by examiner]
US 20140296081A1 · Diehn et al. · 2014 [cited by applicant]
US 20150197785A1 · Carter et al. · 2015 [cited by applicant]
US 20160264973A1 · Aceto et al. · 2016 [cited by applicant]
US 20170073756A1 · Jensen et al. · 2017 [cited by applicant]
US 20170342500A1 · Marquard et al. · 2017 [cited by applicant]
US 20180068083A1 · Cohen et al. · 2018 [cited by applicant]
US 20180251848A1 · Diehn et al. · 2018 [cited by applicant]
US 20200131582A1 · Zhou et al. · 2020 [cited by applicant]
US 20200395100A1 · Eltoukhy · 2020 [cited by examiner]
US 20210207223A1 · Janne et al. · 2021 [cited by applicant]
WO WO2004015608A2 · 2004 [cited by examiner]
WO 2014151117A1 · 2014 [cited by applicant]
WO 2015058175A2 · 2015 [cited by applicant]
WO WO2016094330A2 · 2016 [cited by examiner]
WO 2016094330A3 · 2016 [cited by applicant]
Office Action in U.S. Appl. No. 17/003,631, daed Mar. 20, 2024. [cited by applicant]
Butler, T.M. et al. “Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease” PloSOne (2015) e0136407 (14 pages). [cited by applicant]
Final Office Action for U.S. Appl. No. 17/003,631, dated Dec. 20, 2024. [cited by applicant]
Lebofsky, R. et al. “Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types” Mol Oncol (2014) 9(4):783-790. [cited by applicant]
Office Action for U.S. Appl. No. 17/003,631, dated Aug. 25, 2025. [cited by applicant]